Insulet Corporation (PODD)

Sep 24, 2026

Insulet Corporation (PODD), a medical device company specializing in insulin delivery systems, has experienced a significant stock decline, underperforming the iShares U.S. Medical Devices ETF (IHI) and its rival, DexCom (DXCM). This underperformance is attributed to commercial friction in its Type 2 diabetes segment, lower-than-expected user retention rates, and increased competition, despite beating Q2 earnings expectations. Analysts, however, maintain a "Moderate Buy" rating with a potential upside.

Sep 17, 2026

Baron Capital's Baron SMID Cap ETF (BCSM) exited its position in Insulet Corporation (PODD) during the second quarter of 2026. The fund cited an accelerating competitive landscape and safety issues affecting Insulet's production as reasons for the sale, though it continues to admire the company and keeps it on its radar. Despite the exit, Insulet Corporation (PODD) is considered a global leader in tubeless automated insulin delivery devices, with significant market potential.

Sep 16, 2026

Insulet Corporation is facing a class action lawsuit from Bleichmar Fonti & Auld LLP, alleging the company made false statements about the safety of its Omnipod 5 product, which is linked to manufacturing defects and improper insulin delivery. This legal challenge has contributed to a significant drop in Insulet's stock price, hitting a 52-week low. The lawsuit highlights potential legal and financial risks that could impact the company's future sales and market position in the medical device industry.

Sep 14, 2026

This article analyzes the Q2 earnings of patient monitoring stocks, focusing on ResMed (NYSE:RMD), iRhythm Technologies (NASDAQ:IRTC), Insulet (NASDAQ:PODD), and DexCom (NASDAQ:DXCM). It highlights their revenue performance against analyst expectations, stock reactions, and the broader industry trends including growth drivers like chronic disease prevalence and digital health, and challenges such as high R&D costs and pricing pressures. While the sector generally reported strong Q2 results, individual stock performances varied significantly post-earnings.